2008
DOI: 10.1188/08.onf.385-397
|View full text |Cite
|
Sign up to set email alerts
|

Hepatic Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplant

Abstract: Nurses caring for patients receiving a hematopoietic stem cell transplant must comprehend the proposed etiologies for HSOS and be familiar with the manifestations of the syndrome. Symptom management requires a thorough understanding of affected organ systems.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
20
0

Year Published

2009
2009
2023
2023

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(20 citation statements)
references
References 111 publications
0
20
0
Order By: Relevance
“…The first step is symptomatic treatment with supportive care, which traditionally has been a crucial part of the treatment plan (1,11,27,39,40), and nurses play a key role in providing this (11).…”
Section: Curative Treatmentmentioning
confidence: 99%
“…The first step is symptomatic treatment with supportive care, which traditionally has been a crucial part of the treatment plan (1,11,27,39,40), and nurses play a key role in providing this (11).…”
Section: Curative Treatmentmentioning
confidence: 99%
“…Early recognition, diagnosis and treatment are crucial aspects to limit SOS' severity increasing chances of success [22][23][24][25]. Some authors state that nurses should be involved in a pre-transplant risk assessment to optimize risk factor detection and that they have a crucial role in the early detection of signs and symptoms during and after hospitalization [26][27][28][29][30][31][32][33]. Many clinical issues have been investigated; nursing issues have been studied as well, but there is a lack of specific topics such as assessment, monitoring techniques and care standards.…”
Section: Introductionmentioning
confidence: 99%
“…2,3 The incidence of SOS following stem cell transplantation ranges from 5% to 70% according to various reports, 2 but has been decreased to 30% or less with the advent of nonmyeloablative conditioning and avoidance of cyclophophamide in myeloablative regimens. 3,4 Most patients with mild or moderate SOS will recover. However, severe SOS carries a grave prognosis and typically runs a fulminant clinical course with acute liver failure, coagulopathy, and hepatorenal syndrome.…”
mentioning
confidence: 99%
“…Some of these observations have led to pharmacological interventions involving low-dose heparin, AT III replacement, prostaglandin E1, recombinant tissue plasminogen activator, N-acetylcysteine, or defibrotide. 4 Among these agents, defibrotide, a mixture of porcine-derived phosphodiester oligonucleotides, has been suggested to show promise for the prevention and treatment of SOS. 6 Since SOS contributes to considerable morbidity and mortality, further understanding of its pathogenesis and development of therapeutic or preventive strategies are required.…”
mentioning
confidence: 99%
See 1 more Smart Citation